{"paper_id":"3a53cbbf-68de-4ea2-8d6b-e15d0ae37125","body_text":"Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis Jiqiu Qin, Sheng Sun, Hong Ma, Peng Ding, Qin Yang, Lilai Hu, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3910255/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective Targeting HER2 has significantly improved Overall Survival (OS) for breast cancer (BC) patients. Trastuzumab, a pivotal first-line BC drug, has transformed patient outcomes, and the introduction of trastuzumab deruxtecan (T-DXd) has provided an additional source of hope for patients with BC. The aim of this meta-analysis is to comprehensively appraise the clinical effectiveness and safety aspects of T-DXd in patients with BC. Methods Electronic databases, including PubMed, Web of Science, Embase, and Cochrane Library, were methodically searched until April 6, 2023. Data analysis was performed using Stata 15.0. Result In total, 12 studies were encompassed, consisting of 3 randomized controlled trials (RCTs) providing data and 9 single-arm studies. In the RCTs, T-DXd were shown to OS[ES = 0.62, 95%CI (0.52,0.75); P = 0.826]、PFS[ES = 0.36, 95%CI (0.25,0.51); P = 0.003]、ORR[RR = 2.46,95%CI(2.18,2.78); P = 0.166], compared with Control group, in patients assigned to T-DXd show better outcomes. For single-arm studies, after T-DXd therapy, patients with breast cancer achieved an ORR[ES = 0.57, 95%CI (0.50–0.64)], DCR[ES = 0.94, 95%CI (0.91–0.97)]. Conclusion T-DXd exhibits promising application prospects for breast cancer patients. However, further clinical trials and foundational research are imperative to robustly substantiate our findings. Breast Cancer Trastuzumab deruxtecan Meta-analysis Interstitial Lung Disease Full Text Additional Declarations No competing interests reported. Supplementary Files Supplementarymaterial.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-3910255\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":true,\"archivedVersions\":[],\"articleType\":\"Research Article\",\"associatedPublications\":[],\"authors\":[{\"id\":271165730,\"identity\":\"12635a3f-9849-4753-a0a2-e41184a1245c\",\"order_by\":0,\"name\":\"Jiqiu Qin\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Jiqiu\",\"middleName\":\"\",\"lastName\":\"Qin\",\"suffix\":\"\"},{\"id\":271165731,\"identity\":\"af509a6b-ef65-4ae9-a278-1d96ea0a18ff\",\"order_by\":1,\"name\":\"Sheng Sun\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Sheng\",\"middleName\":\"\",\"lastName\":\"Sun\",\"suffix\":\"\"},{\"id\":271165732,\"identity\":\"70687fc9-5d25-4e55-a020-c9dd9966f27b\",\"order_by\":2,\"name\":\"Hong Ma\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Hong\",\"middleName\":\"\",\"lastName\":\"Ma\",\"suffix\":\"\"},{\"id\":271165733,\"identity\":\"75885db1-c902-4047-b154-75d10ccda263\",\"order_by\":3,\"name\":\"Peng Ding\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Peng\",\"middleName\":\"\",\"lastName\":\"Ding\",\"suffix\":\"\"},{\"id\":271165734,\"identity\":\"9dd7ec83-0432-44d6-b650-ea55378c464c\",\"order_by\":4,\"name\":\"Qin Yang\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Qin\",\"middleName\":\"\",\"lastName\":\"Yang\",\"suffix\":\"\"},{\"id\":271165735,\"identity\":\"8d89a9c6-65b0-4a1c-8786-ac61c0147d3c\",\"order_by\":5,\"name\":\"Lilai Hu\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Lilai\",\"middleName\":\"\",\"lastName\":\"Hu\",\"suffix\":\"\"},{\"id\":271165736,\"identity\":\"636d3833-e0ad-4854-931b-013900f5ab76\",\"order_by\":6,\"name\":\"Deliu Wu\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Deliu\",\"middleName\":\"\",\"lastName\":\"Wu\",\"suffix\":\"\"},{\"id\":271165737,\"identity\":\"b2a32435-e8db-4d0f-bf9f-692b8b2039c3\",\"order_by\":7,\"name\":\"Shaoquan Xiong\",\"email\":\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAz0lEQVRIiWNgGAWjYBADHjb25gMHPvwgQYsMP8+xxIMze0jQYiM5w8f4MAcbEUoNzh/eJvFzBwOPwQ2eD4cZeBjk+cUO4NciOSOtTLL3DFDL7d4NhwssGAxnzk7Ar4VfgsdMgrcNqOXO2Q2HZ/AwJBjcJqCFjf+MmeRfkJYbOQ8O87ARoYWfIcdMGmSL5IwcBuK0AP1SbC0L1AIMZANgIEsQ9gswxDbefNvGYA+MyscfPvywkeeXJqAFpAuI/8M4EgSVw7SMglEwCkbBKMADAHMEQNAw2Rm3AAAAAElFTkSuQmCC\",\"orcid\":\"\",\"institution\":\"Hospital of Chengdu University of Traditional Chinese Medicine\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Shaoquan\",\"middleName\":\"\",\"lastName\":\"Xiong\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2024-01-30 10:17:38\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-3910255/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-3910255/v1\",\"draftVersion\":[],\"editorialEvents\":[],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":50920566,\"identity\":\"2d0d0d5e-13a9-4399-a289-ba8be35beb6a\",\"added_by\":\"auto\",\"created_at\":\"2024-02-09 15:37:40\",\"extension\":\"pdf\",\"order_by\":1,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":582060,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"3.0.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-3910255/v1_covered_42169787-ddf2-4417-8d46-f706d4f9e8fa.pdf\"},{\"id\":50821660,\"identity\":\"c67b57f4-48f4-4c52-b3b4-9dc1bb86a2e1\",\"added_by\":\"auto\",\"created_at\":\"2024-02-07 21:40:00\",\"extension\":\"docx\",\"order_by\":1,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"supplement\",\"size\":345617,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"Supplementarymaterial.docx\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-3910255/v1/f9be93060b04d8a98a8ffa1a.docx\"}],\"financialInterests\":\"No competing interests reported.\",\"formattedTitle\":\"Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis\",\"fulltext\":[],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":false,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":true,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":false,\"isAuthorSuppliedPdf\":true,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":true,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true},\"keywords\":\"Breast Cancer, Trastuzumab deruxtecan, Meta-analysis, Interstitial Lung Disease\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-3910255/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-3910255/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"\\u003ch2\\u003eObjective\\u003c/h2\\u003e \\u003cp\\u003eTargeting HER2 has significantly improved Overall Survival (OS) for breast cancer (BC) patients. Trastuzumab, a pivotal first-line BC drug, has transformed patient outcomes, and the introduction of trastuzumab deruxtecan (T-DXd) has provided an additional source of hope for patients with BC. The aim of this meta-analysis is to comprehensively appraise the clinical effectiveness and safety aspects of T-DXd in patients with BC.\\u003c/p\\u003e\\u003ch2\\u003eMethods\\u003c/h2\\u003e \\u003cp\\u003eElectronic databases, including PubMed, Web of Science, Embase, and Cochrane Library, were methodically searched until April 6, 2023. Data analysis was performed using Stata 15.0.\\u003c/p\\u003e\\u003ch2\\u003eResult\\u003c/h2\\u003e \\u003cp\\u003eIn total, 12 studies were encompassed, consisting of 3 randomized controlled trials (RCTs) providing data and 9 single-arm studies. In the RCTs, T-DXd were shown to OS[ES\\u0026thinsp;=\\u0026thinsp;0.62, 95%CI (0.52,0.75); P\\u0026thinsp;=\\u0026thinsp;0.826]、PFS[ES\\u0026thinsp;=\\u0026thinsp;0.36, 95%CI (0.25,0.51); P\\u0026thinsp;=\\u0026thinsp;0.003]、ORR[RR\\u0026thinsp;=\\u0026thinsp;2.46,95%CI(2.18,2.78); P\\u0026thinsp;=\\u0026thinsp;0.166], compared with Control group, in patients assigned to T-DXd show better outcomes. For single-arm studies, after T-DXd therapy, patients with breast cancer achieved an ORR[ES\\u0026thinsp;=\\u0026thinsp;0.57, 95%CI (0.50\\u0026ndash;0.64)], DCR[ES\\u0026thinsp;=\\u0026thinsp;0.94, 95%CI (0.91\\u0026ndash;0.97)].\\u003c/p\\u003e\\u003ch2\\u003eConclusion\\u003c/h2\\u003e \\u003cp\\u003eT-DXd exhibits promising application prospects for breast cancer patients. However, further clinical trials and foundational research are imperative to robustly substantiate our findings.\\u003c/p\\u003e\",\"manuscriptTitle\":\"Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2024-02-07 21:39:55\",\"doi\":\"10.21203/rs.3.rs-3910255/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"40f0501b-2945-46d8-8973-8336fdfed4d8\",\"owner\":[],\"postedDate\":\"February 7th, 2024\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"posted\",\"subjectAreas\":[],\"tags\":[],\"updatedAt\":\"2024-02-09T15:29:27+00:00\",\"versionOfRecord\":[],\"versionCreatedAt\":\"2024-02-07 21:39:55\",\"video\":\"\",\"vorDoi\":\"\",\"vorDoiUrl\":\"\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-3910255\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-3910255\",\"identity\":\"rs-3910255\",\"version\":[\"v1\"]},\"buildId\":\"qtupq5eGEP_6zYnWcrvyt\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}